Los costes indirectos de la cefalea tensional. Una revisión sistemática de la literatura

Señaris, Juan E. del Llano; Correia, Nuno Nunes; Logusso, Laura Georgina; Rodríguez, María Errea; Roldán, Carlos Bringas

doi:10.1016/j.aprim.2021.102238

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, due to its higher prevalence, the direct cost of medical services and medications for TTH is estimated to be approximately 54% greater than that of migraine (5). Thus, TTH is an important cause of moderate disability, loss of productivity, increased healthcare-related costs, and reduced overall quality-of-life (6).…”

Section: Introductionmentioning

confidence: 99%

The effectiveness of botulinum toxin for chronic tension-type headache prophylaxis: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background A systematic and meta-analysis was conducted to examine the evidence of the effects of botulinum toxin A on chronic tension-type headache. Methods Cochrane, Embase, Ovid, ProQuest, PubMed, Scopus, Web-of-Science databases, and ClinicallTrials.gov registry were systematically searched for studies examining the effects of botulinum toxin A on tension-type headaches. The records were screened by two independent reviewers using pre-determined eligibility criteria. DerSimonian Liard random-effects meta-analyses were performed using the ‘meta’ package (5.2-0) in R (4.2.0). Risk of bias and quality of evidence were assessed using the Cochrane Collaboration’s Tool RoB 2 and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Clinical significance was determined using pre-defined minimal clinically important differences. Results Eleven controlled trials were included (390 botulinum toxin A, 297 controls). Botulinum toxin A was associated with significant improvements in standardized headache intensity (−0.502 standard deviations [−0.945, −0.058]), headache frequency (−2.830 days/month [−4.082, −1.578]), daily headache duration (−0.965 [−1.860, −0.069]) and the frequency of acute pain medication use (−2.200 days/month [−3.485, −0.915]) vs controls. Botulinum toxin A-associated improvements exceeded minimal clinically important differences for headache intensity, frequency, and acute pain medication use. A 79% (28%, 150%) greater response rate was observed for botulinum toxin A vs controls in improving chronic tension-type headache. Treatment of eight chronic tension-type headache patients was sufficient to elicit a therapeutic response in one patient. Conclusions Corroborating the current mechanistic evidence, our meta-analysis supports the utility of botulinum toxin A for managing chronic tension-type headaches. However, due to limitations in the quality of evidence, adequately-powered high-quality controlled trials examining the effects of Botulinum toxin A on chronic tension-type headache are warranted. Registration Protocol preregistered in PROSPERO International Prospective Register of Systematic Reviews (CRD42020178616)

show abstract

Section: Introductionmentioning

confidence: 99%

The effectiveness of botulinum toxin for chronic tension-type headache prophylaxis: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

Non-Migraine Head Pain and Botulinum Toxin

Farham,

Onan,

Martelletti

2024

Toxins

View full text Add to dashboard Cite

Botulinum toxin A (BT-A), a potential neurotoxin produced by the bacterium Clostridium botulinum, is known for its ability to prevent the release of acetylcholine at the neuromuscular synapse, leading to temporary muscle paralysis. BT-A is used for a wide range of therapeutic applications. Several studies have shown mechanisms beyond the inhibition of acetylcholine release for pain control. BT-A inhibits the release of neurotransmitters associated with pain and inflammation, such as glutamate, CGRP, and substance P. Additionally, it would be effective in nerve entrapment leading to neuronal hypersensitivity, which is known as a new pathogenesis of painful conditions. BT-A has been applied to the treatment of a wide variety of neurological disorders. Since 2010, BT-A application has been approved and widely used as a chronic migraine prophylaxis. Moreover, due to its effects on pain through sensory modulation, it may also be effective for other headaches. Several studies using BT-A, at different doses and administration sites for headaches, have shown beneficial effects on frequency and severity. In this review, we provide an overview of using BT-A to treat primary and secondary headache disorders.

show abstract

Los costes indirectos de la cefalea tensional. Una revisión sistemática de la literatura

Cited by 2 publications

References 24 publications

The effectiveness of botulinum toxin for chronic tension-type headache prophylaxis: A systematic review and meta-analysis

The effectiveness of botulinum toxin for chronic tension-type headache prophylaxis: A systematic review and meta-analysis

Non-Migraine Head Pain and Botulinum Toxin

Contact Info

Product

Resources

About